A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double-blind method

Atsushi Saito, Mitsuo Sakamoto, Akira Saito, Mitsuhide Ohmichi, Yohmei Hiraga, Kenjiro Kikuchi, Yoshinobu Ohsaki, Nobuhiro Sasaki, Hiroyuki Matsumoto, Toshihiro Suda, Moriyasu Tsuzino, Yuichi Hirai, Hiroshi Inoue, Masami Yoshida, Takashi Mouri, Hitoshi Kobayashi, Shinichi Chiba, Takashi Ito, Katsuyoshi Moriya, Takeshi BandoKenichi Takeuchi, Yukio Tanifuji, Kunio Shirato, Yasuo Tanno, Makoto Takahashi, Masahiro Sakamoto, Toshihiro Nukiwa, Akira Watanabe, Kazuo Sato, Mitsunobu Homma, Nobuo Ito, Kenji Yanase, Kunio Dote, Akira Ohishi, Kiyoshi Fukuda, Masataka Katsu, Osamu Sakai, Kohya Shiba, Hiroyuki Kobayashi, Susumu Sakayori, Hiroshi Miura, Hidehiro Watanabe, Kaoru Shimada, Shinichi Oka, Hirotaka Sugiyama, Takashi Inamatsu, Yasuyuki Sano, Yasuo Arai, Mamoru Otomo, Matsunobu Sukou, Hideo Kobayashi, Susumu Sikata, Harumi Shishido, Keiko Tsuchihashi, Koichiro Nakata, Eiyasu Tsuboi, Tatsuo Nakatani, Yoshitaka Nakamori, Izumi Hayashi, Masaru Koyama, Takao Okubo, Kenji Tani, Tamotsu Kaneko, Masanori Matsumura, Shigeto Takagi, Hideyuki Hasegawa, Hiroyuki Numata, Tsutomu Fukuda, Shoichiro Irimajiri, Yasuo Matsuoka, Mitsuo Obana, Fumio Matsumoto, Iwao Sakurai, Shigeki Odagiri, Kenichi Takahashi, Kaneo Suzuki, Masaaki Arakawa, Koichi Wada, Fumihide Iwata, Yoshinori Shimazu, Hiroyuki Sega, Hiroki Tsukada, Takashi Kawashima, Nobuki Aoki, Yasutoshi Suzuki, Osamu Sekine, Atsuhiko Sato, Yutaka Nakano, Ryoji Tamura, Hideki Suganuma, Masahiro Shirai, Sumio Kawakatsu, Takayoshi Watanabe, Jinichiro Akiyama, Takeshi Yagi, Katsutaka Torikai, Syusaku Fukaya, Akiei Mizutani, Toshihiko Takeuchi, Yasuo Yamada, Hidekazu Hanaki, Makoto Kawakami, Yoshimitsu Hayashi, Tomoyuki Tashiro, Ryuji Nomura, Kenzo Takagi, Yasunobu Noda, Hideo Gonda, Hiroyuki Taniguchi, Saburo Izumi, Fumiyuki Kuze, Akio Niimi, Yosiro Mochizuki, Yasuji Nakahara, Tetsuji Kawamura, Tadamitsu Kishimoto, Yoshiro Tanio, Tsuyoshi Igarashi, Kiyoshi Komuta, Masami Ito, Takeshi Okumoto, Masahide Mori, Kiyoshi Jozaki, Seibun Yonezu, Fumio Miki, Kazuya Higashino, Takashi Nakano, Mitsutomi Miyake, Toshihiko Nishian, Shinichiro Iida, Sayaka Yamamoto, Akio Maebo, Takahiko Yoshimoto, Takashi Sonoda, Masakiyo Nakagawa, Masataka Hirabayashi, Naoki Togawa, Masao Yoshida, Yoshitaka Kawai, Rinzo Soejima, Niro Okimoto, Toshiharu Matsushima, Makoto Kimura, Michio Yamakido, Shinichi Ishioka, Masao Kuwahara, Nobuhiro Mochizuki, Teruomi Miyazawa, Masao Doi, Kenichi Arita, Kazuhiro Daido, Tsuyoshi Ejima, Yoshiro Sawae, Koji Takaki, Minoru Yoshida, Takamichi Aritomi, Kotaro Oizumi, Yoichiro Ichikawa, Tsuneaki Shiraishi, Yoshiyuki Mitsutake, Fumio Tanaka, Takaoki Ohtsuka, Masashi Kawahara, Shinzo Kawaguchi, Tomotaka Kawayama, Yoshihiro Sato, Yoshiaki Honda, Tsuneo Ishibashi, Masahiro Takamoto, Akira Kajiki, Yasuko Harada, Masayuki Ando, Moritaka Suga, Katsumasa Tokunaga, Kiyoshi Shima, Shinobu Takenaka, Kohei Hara, Shigeru Kohno, Mitsuo Kaku, Nobuhiro Koga, Yuichi Inoue, Yuko Yamasita, Shingo Sakata, Takeshi Fujii, Kenji Irifune, Kazunori Shimoguchi, Yoshitsugu Miyazaki, Keizo Matsumoto, Tsuyoshi Nagatake, Masakazu Takasugi, Mikio Fujishita, Masaru Nasu, Tohru Yamasaki, Yoichiro Goto, Kaoru Nakama, Soichi Inoue, Shigeru Matsukura, Hideo Mashimoto, Hiroshi Mukae, Atsushi Saito, Hiroshi Fukuhara, Tominori Oyakawa, Koichi Deguchi, Mitsuyoshi Nakashima

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Abstract

To objectively evaluate the efficacy, safety and usefulness of the newly developed penem oral antibiotic, ritipenem acoxil (RIPM-AC), against bacterial pneumonia, we conducted a multi-center double-blind comparative study using cefotiam hexetil (CTM-HE) as the control drug. Both RIPM-AC and CTM-HE were orally administered at 200 mg t.i.d. for 14 days, in principle. The results were as follows: The total number of patients enrolled in this trial was 208, of which 152 cases (RIPM-AC group: 73, CTM-HE group: 79) were evaluable for clinical efficacy. 1. The clinical efficacy rates (excellent + good) were 91.8% (67/73) in the RIPM-AC group and 94.9% (75/79) in the CTM-HE group. There was no significant difference between the two groups, and the clinical equivalency of RIPM-AC to CTM-HE was demonstrated. 2. In the patients enrolled in the evaluation of clinical efficacy, the eradication rates of the causative organisms were 84.6% (22/26) in the RIPM-AC group and 91.7% (22/24) in the CTM-HE group, with no significant difference between the two groups. 3. Side effects were noted in 9 cases (9.6%) of the RIPM-AC group and 5 cases (4.9%) of the CTM-HE group. Abnormal laboratory test findings were observed in 23 cases (26.7%) of the RIPM-AC group and 15 cases (15.6%) of the CTM-HE group. There were no significant differences between the two groups in the incidence of side effects nor of abnormal laboratory test findings. In the safety evaluation, RIPM-AC was judged to be safe in 64 cases (68.1%) and CTM-HE in 82 cases (80.4%), with no significant difference. 4. The usefulness rates (markedly useful + useful) were 86.5% (64/74) in the RIPM-AC group and 92.5% (74/80) in the CTM-HE group. There was no significant difference between the two groups. Since RIPM-AC showed clinical efficacy similar to those of CTM-HE and posed no particular safety problems, it is expected to be a useful antibiotic for the treatment of bacterial pneumonia.

Original languageEnglish
Pages (from-to)63-68
Number of pages6
JournalJapanese Journal of Antibiotics
Volume49
Issue number2
Publication statusPublished - 02-1996

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double-blind method'. Together they form a unique fingerprint.

Cite this